FibroGen to Report Third Quarter 2021 Financial Results
October 26 2021 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021
financial results on Tuesday, November 9 after the market close.
FibroGen will also conduct a conference call on that day at 5:00
p.m. ET (2:00 p.m. PT) with the investment community to further
detail the company's corporate and financial performance.
Conference Call and Audio Webcast Interested
parties may access a live audio webcast of the conference call via
the FibroGen website at
https://fibrogen.gcs-web.com/events-and-presentations/events. It is
recommended that listeners access the website 15 minutes prior to
the start of the call to download and install any necessary audio
software.
Dial-In InformationLive (U.S./Canada): (877)
658-9081Live (International): (602) 563-8732Confirmation number:
1747879
A replay of the webcast and investor presentation will be
available shortly after the call for a period of 7 days. To access
the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406
(international) and use passcode 1747879.
About FibroGen FibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing, and
commercializing a pipeline of first-in-class therapeutics. The
Company applies its pioneering expertise in hypoxia-inducible
factor (HIF) and connective tissue growth factor (CTGF) biology to
advance innovative medicines for the treatment of unmet needs. The
Company is currently developing and commercializing roxadustat, an
oral small molecule inhibitor of HIF prolyl hydroxylase activity
for anemia associated with chronic kidney disease (CKD), anemia
associated with myelodysplastic syndromes (MDS), and for
chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human
monoclonal antibody, is in clinical development for the treatment
of idiopathic pulmonary fibrosis (IPF), locally advanced
unresectable pancreatic cancer (LAPC), and Duchenne muscular
dystrophy (DMD). FibroGen recently expanded its research and
development portfolio to include product candidates in the
immuno-oncology and autoimmune space. For more information, please
visit www.fibrogen.com.
Contacts: FibroGen, Inc.
Investors:Michael Tung, M.D.Corporate Strategy
/ Investor Relations1.415.978.1434mtung@fibrogen.com
Media:Meichiel KeenanPublic
Affairsmkeenan@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024